☆ 4.7 News Item

Special report: Policy: Rituximab for follicular non-Hodgkin lymphoma

LANCET ONCOLOGY (2008)

期刊

LANCET ONCOLOGY

卷 9, 期 4, 页码 320-321

出版社

LANCET LTD

DOI: 10.1016/S1470-2045(08)70036-6

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Hematology

Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group

Dennis A. Eichenauer, Horst Muller, Leonard Elger, Helen Goergen, Michael Fuchs, Stefanie Kreissl, Boris Boll, Volker Diehl, Bastian von Tresckow, Peter Borchmann, Andreas Engert

Summary: NHL after cHL is a rare event that primarily affects older individuals, with a five-year event-free survival and overall survival estimates of 36.9% and 44.2% respectively.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Hodgkin Lymphoma: A Special Microenvironment

Giuseppina Opinto, Claudio Agostinelli, Sabino Ciavarella, Attilio Guarini, Eugenio Maiorano, Giuseppe Ingravallo

Summary: Classical Hodgkin's lymphoma is a particular lymphoma characterized by few tumor cells surrounded by an inflammatory microenvironment. The tumor cells reprogram and evade antitumor mechanisms of normal cells, while the microenvironment cells are essential for the growth and survival of the tumor cells. Recent advances in gene expression profiling analysis have been applied to study the microenvironment component in cHL, and therapies targeting both neoplastic cells and the cellular components of the background have been described.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study

Virginie Nerich, Christophe Guyeux, Michel Henry-Amar, Raphael Couturier, Catherine Thieblemont, Vincent Ribrag, Herve Tilly, Corinne Haioun, Rene-Olivier Casasnovas, Franck Morschhauser, Pierre Feugier, David Sibon, Loic Ysebaert, Emmanuelle Nicolas-Virelizier, Florence Broussais-Guillaumot, Gandhi L. Damaj, Jean-Philippe Jais, Gilles Salles, Macha Woronoff-Lemsi, Nicolas Mounier

Summary: This study focused on the health care resource use and associated costs in 1671 long-term NHL survivors in France. The results showed that most survivors utilized health care resources, with hospitalizations and outpatient treatments being major cost drivers. Several factors were found to have significant relationships with health care costs, but rituximab or autologous stem cell transplantation did not affect costs.

CANCER (2022)

添加到收藏夹

Article Oncology

Primary follicular lymphoma of the uterine cervix: A case report

Alkis Matsas, Panagiotis Christopoulos, Charalampos Karachalios, Orestis Savranakis, Leonidas Marinos, Nikos F. Vlahos, Theodoros Panoskaltsis

Summary: This case report describes a rare incidence of primary cervical follicular lymphoma, diagnosed during the management of concurrent cervical intraepithelial neoplasia. The report highlights the necessity of adhering to guidelines for management of abnormal cervical cytology, as well as the importance of expert pathological review and personalized management.

ONCOLOGY LETTERS (2023)

添加到收藏夹

Review Oncology

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas

Lori A. Leslie

Summary: When choosing therapy for patients with indolent non-Hodgkin lymphoma, factors such as age and comorbid conditions need to be considered. While incurable, iNHL is a chronic disease with a long overall survival period. Despite advancements in available therapies, progress in iNHL has been slow.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont

Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.

NATURE MEDICINE (2022)

添加到收藏夹

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

64Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression

Inki Lee, Ilhan Lim, Kyo Chul Lee, Hye Jin Kang, Sang Moo Lim

Summary: Cu-64-DOTA-rituximab PET/CT was performed on two patients with B-cell non-Hodgkin lymphoma, and it was found to be more sensitive in detecting lesions compared to F-18-FDG PET/CT. It was confirmed that there was no discernible Cu-64-DOTA-rituximab uptake in the tumor other than lymphoma. Cu-64-DOTA-rituximab PET/CT could be a powerful tool for the diagnosis and monitoring treatment response of lymphoma due to its ability to image CD20 expression.

CLINICAL NUCLEAR MEDICINE (2023)

添加到收藏夹

Article Oncology

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson, Julio C. Chavez, Alison R. Sehgal, Basem M. William, Javier Munoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, Henry Chi Hang Fung, Joseph Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu

Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial

G. A. Amos Burke, Luciana Vinti, Edita Kabickova, Auke Beishuizen, Nurdan Tacyildiz, Anne Uyttebroeck, Hyoung Jin Kang, Flavio Luisi, Veronique Minard-Colin, Birgit Burkhardt, Monelle Tamegnon, Steven Sun, Madeliene Curtis, Sanjay Deshpande, Kerri Nottage, Angela Howes, Srimathi Srinivasan, Deepa Bhojwani, Robin Norris, Mitchell Cairo

Summary: The results of the SPARKLE trial showed that continued assessment of ibrutinib with modified rituximab or rituximab, vincristine, ifosfamide, carboplatin, idarubicin, and dexamethasone in pediatric patients with relapsed/refractory mature B-cell non-Hodgkin lymphoma (B-NHL) did not provide a significant benefit in event-free survival. The overall response rate and overall survival were slightly higher in the ibrutinib plus chemotherapy group compared to chemotherapy alone. However, all patients in both treatment arms experienced grade >= 3 treatment-emergent adverse events. Ibrutinib exposure in pediatric patients was within the target range observed in adults.

BLOOD ADVANCES (2023)

添加到收藏夹

Review Oncology

HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies

Xing Cao, Yafei Wang, Panyun Li, Wei Huang, Xiaojuan Lu, Hongda Lu

Summary: HBV-R is a common and dangerous complication during the treatment of NHL patients, potentially leading to increased morbidity and mortality. Immunosuppressive therapies increase the risk of HBV-R, highlighting the importance of enhanced screening and monitoring measures.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma

Alexander M. Newman, Masood Zaka, Peixun Zhou, Alex E. Blain, Amy Erhorn, Amy Barnard, Rachel E. Crossland, Sarah Wilkinson, Amir Enshaei, Julian De Zordi, Fiona Harding, Mary Taj, Katrina M. Wood, Despina Televantou, Suzanne D. Turner, G. A. Amos Burke, Christine J. Harrison, Simon Bomken, Chris M. Bacon, Vikki Rand

Summary: Research shows that TP53 gene abnormalities are associated with inferior survival rates in children with B-cell non-Hodgkin lymphoma, especially in high-risk patients. These findings provide a novel molecular risk stratifier for more personalized treatment protocols.

LEUKEMIA (2022)

添加到收藏夹

Article Medicine, General & Internal

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim M. Linton, Martine E. D. Chamuleau, David John Lewis, Anna Sureda Balari, David Cunningham, Roberto S. Oliveri, Brian Elliott, Dena DeMarco, Ada Azaryan, Christopher Chiu, Tommy Li, Kuo-mei Chen, Tahamtan Ahmadi, Pieternella J. Lugtenburg

Summary: This study aimed to evaluate the safety and recommended dose of a novel bispecific antibody epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results showed that the full dose of 48 mg was identified as the recommended phase 2 dose, and no maximum tolerated dose was reached during the treatment. Epcoritamab demonstrated good antitumor activity in some patients during the study.

LANCET (2021)

添加到收藏夹

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

C. Perry, E. Luttwak, R. Balaban, G. Shefer, M. M. Morales, A. Aharon, Y. Tabib, Y. C. Cohen, N. Benyamini, O. Beyar-Katz, M. Neaman, R. Vitkon, N. Keren-Khadmy, M. Levin, Y. Herishanu, I Avivi

Summary: Patients with B-cell non-Hodgkin lymphoma (B-NHL) undergoing R/Obi treatment have impaired humoral response to the BNT162b2 mRNA COVID-19 vaccine. Longer time since exposure to R/Obi is associated with improved response rates to the COVID-19 vaccine. Multi-variable analysis reveals predictors for a positive serological response.

BLOOD ADVANCES (2021)

添加到收藏夹

Review Immunology

Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials

Jinjin Wang, Hui Zhou, Mingchun Mu, Ailin Zhao, Zhaolun Cai, Linfeng Li, Mengyao Wang, Ting Niu

Summary: This meta-analysis evaluated the efficacy and safety of Copanlisib in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). The results showed that both Copanlisib monotherapy and combination therapy with rituximab were effective in R/R B-NHL patients, with manageable treatment-related adverse events.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells

Mario Bunse, Janina Pfeilschifter, Julia Bluhm, Maria Zschummel, Jara J. Joedicke, Anthea Wirges, Helen Stark, Vivien Kretschmer, Markus Chmielewski, Wolfgang Uckert, Hinrich Abken, Joerg Westermann, Armin Rehm, Uta E. Hoepken

Summary: The study demonstrates that CAR-T cells targeting CXCR5 effectively inhibit tumor growth by depleting both B cells and follicular T helper cells in lymphoma models, suggesting a promising treatment strategy for nodal B-NHLs.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

News Item Oncology

NICE guidance on axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

Nwamaka Umeweni, Boglarka Mikudina, Frances Sutcliffe, Andrew Stevens

LANCET ONCOLOGY (2015)

添加到收藏夹

Editorial Material Health Care Sciences & Services

Secular trends and evaluation of complex interventions: the rising tide phenomenon

Yen-Fu Chen, Karla Hemming, Andrew J. Stevens, Richard J. Lilford

BMJ QUALITY & SAFETY (2016)

添加到收藏夹

Article Medicine, General & Internal

Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study

Derek J. Ward, Edward Hammond, Luan Linden-Phillips, Andrew J. Stevens

BMJ OPEN (2015)

添加到收藏夹

News Item Oncology

NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments

Caroline J. Hall, Sally Doss, Nicola Hay, Frances Sutcliffe, Andrew Stevens

LANCET ONCOLOGY (2016)

添加到收藏夹

Review Medicine, General & Internal

Past speculations of the future: a review of the methods used for forecasting emerging health technologies

Lucy Doos, Claire Packer, Derek Ward, Sue Simpson, Andrew Stevens

BMJ OPEN (2016)

添加到收藏夹

Article Ethics

National Institute for Health and Clinical Excellence appraisal and ageism

Andrew Stevens, Nick Doyle, Peter Littlejohns, Mary Docherty

JOURNAL OF MEDICAL ETHICS (2012)

添加到收藏夹

News Item Oncology

NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours

Anwar Jilani, Zoe Garrett, Frances Sutcliffe, Andrew Stevens

LANCET ONCOLOGY (2012)

添加到收藏夹

News Item Oncology

NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib

Scott Goulden, Frances Sutcliffe, Andrew Stevens

LANCET ONCOLOGY (2012)

添加到收藏夹

News Item Oncology

NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma

Linda J. Landells, Carl Prescott, Nicola Hay, Frances Sutcliffe, Andrew Stevens

LANCET ONCOLOGY (2014)

添加到收藏夹

Article Health Care Sciences & Services

At the Center of Health Care Policy Making: The Use of Health Technology Assessment at NICE

Andrew J. Stevens, Carole Longson

MEDICAL DECISION MAKING (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Patterns of Warfarin Use in Subgroups of Patients with Atrial Fibrillation: A Cross-Sectional Analysis of 430 General Practices in the United Kingdom

Mohammed A. Mohammed, Tom Marshall, Krishnarajah Nirantharakumar, Andrew Stevens, David Fitzmaurice

PLOS ONE (2013)

添加到收藏夹

Article Multidisciplinary Sciences

The Combined Influence of Distance and Neighbourhood Deprivation on Emergency Department Attendance in a Large English Population: A Retrospective Database Study

Gavin M. Rudge, Mohammed A. Mohammed, Sally C. Fillingham, Alan Girling, Khesh Sidhu, Andrew J. Stevens

PLOS ONE (2013)

添加到收藏夹

Article Medicine, General & Internal

The findings of the Mid-Staffordshire Inquiry do not uphold the use of hospital standardized mortality ratios as a screening test for 'bad' hospitals

M. A. Mohammed, R. Lilford, G. Rudge, R. Holder, A. Stevens

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

Decline in new drug launches: myth or reality? Retrospective observational study using 30 years of data from the UK

Derek J. Ward, Orsolina I. Martino, Sue Simpson, Andrew J. Stevens

BMJ OPEN (2013)

添加到收藏夹

Article Medicine, General & Internal

How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012

Derek J. Ward, Angharad Slade, Tracey Genus, Orsolina I. Martino, Andrew J. Stevens

BMJ OPEN (2014)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.